Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells

Oncology Reports

Volumn 26, Issue 6, 2011, Pages 1581-1586

  Cho, Sung Bum ^a   Park, Young Lan ^a   Song, Young A ^a   Kim, Kyu Yeol ^a   Lee, Gi Hoon ^a   Cho, Dae Ho ^a   Myung, Dae Seong ^a   Park, Kang Jin ^a   Lee, Wan Sik ^a   Chung, Ik Joo ^a   Choi, Sung Kyu ^a   Kim, Kyung Keun ^a   Joo, Young Eun ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Hepatocellular carcinoma; Recepteur d'origine nantais; Signal transduction; Tumor progression

Indexed keywords

CASPASE 3; CYCLIN D1; CYCLIN D3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN RON; PROTEIN TYROSINE KINASE; RAF PROTEIN; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; MODULATION; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

APOPTOSIS REGULATORY PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL MOVEMENT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; PHENOTYPE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 80053499870     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1435     Document Type: Article

References (39)

1. Bruix J and Sherman M: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
2. Song TJ, Ip EW and Fong Y: Hepatocellular carcinoma: current surgical management. Gastroenterology 127 (Suppl 1): S248-S260, 2004.
3. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL and Lok AS: Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41: 707-716, 2005.
4. Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572, 2002.
5. Townson JL and Chambers AF: Dormancy of solitary metastatic cells. Cell Cycle 5: 1744-1750, 2006.
6. Robertson SC, Tynan JA and Donoghue DJ: RTK mutations and human syndromes: when good receptors turn bad. Trends Genet 16: 265-271, 2000.
7. Manning G, Whyte DB, Martinez R, Hunter T and Sudarsanam S: The protein kinase complement of the human genome. Science 298: 1912-1934, 2002.
8. Van de Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I and Resau J: Met-HGF/SF: tumorigenesis, invasion and metastasis. Ciba Found Symp 212: 119-130, 1997.
9. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology 61: 1-13, 2001.
10. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103: 211-225, 2000.
11. Van der Geer P, Hunter T and Lindberg RA: Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10: 251-337, 1994.
12. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
13. Lu Y, Yao HP and Wang MH: Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett 257: 157-164, 2007.
14. Leonis MA, Thobe MN and Waltz SE: Ron-receptor tyrosine kinase in tumorigenesis and metastasis. Future Oncol 3: 441-448, 2007.
15. Camp ER, Liu W, Fan F, Yang A, Somcio R and Ellis LM: RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol 12: 273-281, 2005.
16. Wang MH, Yao HP and Zhou YQ: Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers. Acta Pharmacol Sin 27: 641-650, 2006.
17. Wang MH, Wang D and Chen YQ: Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 24: 1291-1300, 2003.
18. Wagh PK, Peace BE and Waltz SE: Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 100: 1-33, 2008.
19. Danilkovitch-Miagkova A: Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets 3: 31-40, 2003.
20. Chen YQ, Zhou YQ, Fu LH, Wang D and Wang MH: Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais. Carcinogenesis 23: 1811-1819, 2002.
21. Peace BE, Toney-Earley K, Collins MH and Waltz SE: Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res 65: 1285-1293, 2005.
22. Maggiora P, Marchio S, Stella MC, et al: Overexpression of the RON gene in human breast carcinoma. Oncogene 16: 2927-2933, 1998.
23. Lee CT, Chow NH, Su PF, Lin SC, Lin PC and Lee JC: The prognostic significance of RON and MET coexpression in patients with colorectal cancer. Dis Colon Rectum 5: 1268-1274, 2008.
24. Willett CG, Wang MH, Emanuel RL, et al: Macrophage-stimulating protein and its receptor in non-small cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration. Am J Respir Cell Mol Biol 18: 489-496, 1998.
25. Maggiora P, Lorenzato A, Fracchioli S, et al: The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 288: 382-389, 2003.
26. Thomas RM, Toney K, Fenoglio-Preiser C, et al: The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 67: 6075-6082, 2007.
27. Cheng HL, Liu HS, Lin YJ, et al: Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 92: 1906-1914, 2005.
28. Chen Q, Seol DW, Carr B and Zarnegar R: Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 26: 59-66, 1997.
29. Leonis MA, Toney-Earley K, Degen SJ and Waltz SE: Deletion of the Ron receptor tyrosine kinase domain in mice provides protection from endotoxin-induced acute liver failure. Hepatology 36: 1053-1060, 2002.
30. Stuart WD, Kulkarni RM, Gray JK, Vasiliauskas J, Leonis MA and Waltz SE: Ron receptor regulates Kupffer cell-dependent cytokine production and hepatocyte survival following endotoxin exposure in mice. Hepatology 53: 1618-1628, 2011.
31. Zimmermann S and Moelling K: Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286: 1741-1744, 1999.
32. Moelling K, Schad K, Bosse M, Zimmermann S and Schweneker M: Regulation of Raf-Akt Cross-talk. J Biol Chem 277: 31099-31106, 2002.
33. Mason EF and Rathmell JC: Cell metabolism: an essential link between cell growth and apoptosis. Biochim Biophys Acta 1813: 645-654, 2011.
34. DeBerardinis RJ, Lum JJ, Hatzivassiliou G and Thompson CB: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20, 2008.
35. Morgan DO: Principles of CDK regulation. Nature 374: 131-134, 1995.
36. Grana X and Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211-219, 1995.
37. Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9: 59-71, 2005.
38. Chappell WH, Steelman LS, Long JM, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2: 135-164, 2011.
39. Chung E and Kondo M: Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development. Immunol Res 49: 248-268, 2011.